FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...
Biomea Fusion: Recent Rally May Not Last, Despite Upcoming Data Catalysts
I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...
Fintel on MSN4d
Truist Securities Upgrades Biomea Fusion (BMEA)
Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...
Fintel on MSN6d
Rodman & Renshaw Upgrades Biomea Fusion (BMEA)
Fintel reports that on September 26, 2024, Rodman & Renshaw upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...
Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s ...
Biomea Fusion Hold Rating: FDA Clearance and Increased Price Target Amid Cautious Optimism
Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...
bovnews2d
Truist Just Upgraded Biomea Fusion Inc (BMEA) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.46% ...
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
Biomea Fusion, Inc. BMEA shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on ...
Nasdaq7d
Truist Securities Upgrades Biomea Fusion (BMEA)
Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from Hold to Buy. As of September 25, 2024, the average one-year price target ...